{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:11:06Z","timestamp":1762348266251,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Blue Earth Therapeutics Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.nucmedbio.2025.109042","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T10:11:11Z","timestamp":1749377471000},"page":"109042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation"],"prefix":"10.1016","volume":"146-147","author":[{"given":"Caroline","family":"Foxton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Waldron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freja","family":"Pretzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke Veggerby","family":"Gr\u00f8nlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias Wikke","family":"Hallund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2025.109042_bb0005","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0015","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"NEJM"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34","author":"Sartor","year":"2023","journal-title":"Ann Oncol"},{"author":"US Food and Drug Administration","key":"10.1016\/j.nucmedbio.2025.109042_bb0025"},{"author":"European Medicines Agency","key":"10.1016\/j.nucmedbio.2025.109042_bb0030"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0035","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0040","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0045","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.nucmedbio.2025.109042_bb0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMaddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol"},{"author":"NIH US National Library of Medicine ClinicalTrials.gov","key":"10.1016\/j.nucmedbio.2025.109042_bb0055"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0060","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2967\/jnumed.123.265970","article-title":"An intra-patient dosimetry comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in patients with metastatic castrate-resistant prostate cancer","volume":"64","author":"Rinscheid","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy-like picture","volume":"83","author":"Schafer","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0075","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2967\/jnumed.121.263371","article-title":"Synthesis and preclinical evaluation of 177Lu-labeled radiohybrid PSMA ligands (rhPSMAs) for endoradiotherapy of prostate cancer","volume":"63","author":"Wurzer","year":"2022","journal-title":"J Nucl Med"},{"author":"US Food and Drug Administration","key":"10.1016\/j.nucmedbio.2025.109042_bb0080"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2967\/jnumed.124.268508","article-title":"Preclinical evaluation of 177Lu-rhPSMA-10.1, a novel radiopharmaceutical for prostate cancer: biodistribution and therapeutic efficacy","volume":"66","author":"Foxton","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0090","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2967\/jnumed.123.266741","article-title":"First safety and efficacy data with the radiohybrid 177Lu-rhPSMA-10.1 for the treatment of metastatic prostate cancer","volume":"65","author":"Dierks","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0095","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-024-06959-5","article-title":"Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T","volume":"52","author":"G\u00e4ble","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0105","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","article-title":"What\u2019s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns","volume":"48","author":"Ruschoff","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0110","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/pros.24549","article-title":"PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy","volume":"83","author":"Derlin","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0115","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2967\/jnumed.120.243295","article-title":"Radionuclide therapy in prostate cancer: from standalone to combination PSMA theranostics","volume":"62","author":"Sandhu","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0120","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/onc.2013.497","article-title":"Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy","volume":"33","author":"Drake","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"Number 16 suppl","key":"10.1016\/j.nucmedbio.2025.109042_bb0130","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.trecan.2020.01.015","article-title":"DNA-PK, nuclear mTOR, and the androgen pathway in prostate cancer","volume":"6","author":"Giguere","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0145","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.7150\/thno.15311","article-title":"Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib","volume":"6","author":"Nonnekens","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211090","article-title":"Castration-resistant prostate cancer: androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death","volume":"14","author":"Reddy","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0160","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying drug combination synergy along potency and efficacy axes","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Syst"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0170","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0175","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003226.07","article-title":"Radioligand therapy with 177Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer: oncological outcomes and toxicity profile","volume":"209","author":"Demirkol","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0180","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0185","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s12149-021-01649-w","article-title":"177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements","volume":"35","author":"Cao","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41181-024-00246-2","article-title":"Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies","volume":"9","author":"Wurzer","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0200","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"NEJM"},{"author":"US Food and Drug Administration","key":"10.1016\/j.nucmedbio.2025.109042_bb0205"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.100983","article-title":"Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations","volume":"50","author":"Hu","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0215","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-019-0134-5","article-title":"MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer","volume":"22","author":"Nickols","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0220","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.3390\/ijms20102530","article-title":"Biological rationale for targeting MEK\/ERK pathways in anti-cancer therapy and to potentiate tumour responses to radiation","volume":"20","author":"Marampon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0225","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.trecan.2020.05.011","article-title":"DNA damage repair deficiency in prostate cancer","volume":"6","author":"Burdak-Rothkamm","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0230","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/CMR.0000000000000682","article-title":"Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis","volume":"30","author":"Ziegler","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0235","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1158\/1538-7445.AM2019-4864","article-title":"Abstract 4864: targeted melanoma therapies as radiosensitizers","volume":"79","author":"Smith","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0240","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1078-0432.CCR-19-2268","article-title":"Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer","volume":"26","author":"Hammer","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2025.109042_bb0245","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood-2023-187508","article-title":"Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms","volume":"143","author":"Diamond","year":"2023","journal-title":"Blood"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:06:20Z","timestamp":1762347980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805125000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":49,"alternative-id":["S0969805125000514"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109042","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109042"}}